Clin Chem:床旁检测c反应蛋白,葡萄糖,血红蛋白测试的可交换性全血外部质量评估材料

2019-08-03 不详 MedSci原创

一般来说,外部质量评估<span lang="EN-US" style="font-size:12.0pt;mso-bidi-font-size:14.0pt;font-family:&quot;Calibri&quot;,&quot;sans-serif&quot;; mso-fareast-font-family:宋体;mso-bidi-font-family:&quot;Times New

一般来说,外部质量评估(EQA)的最佳情况是使用可交换材料。之前对于床旁检测全血检测材料的可交换性尚无研究。本研究的目的是确定在挪威常用的POC仪器的挪威质量改进实验室检查(Noklus)组织的内部全血EQA材料用于C-反应蛋白(CRP),葡萄糖和血红蛋白的可交换性,并确定为每种分析物使用共同目标值的可能性。

本研究遵循临床与实验室标准协会指南进行研究。EQA材料是稳定的EDTA静脉全血,包含不同浓度的分析物。使用17POC3种医院仪器对EQA材料和本地常规患者样本进行分析。采用戴明回归分析对各仪器之间的可换性进行评估,预测区间为95%

研究显示,EQA材料对所有CRP和血红蛋白POC仪器均具有可交换性,而对葡萄糖,在最低浓度分析[126.0 mg/dL (7.0 mmol/L)]和所有浓度分析的3POC仪器均可交换。

使用CRP和血红蛋白POC仪器的Noklus EQA的结果与参考目标值相似,而使用葡萄糖POC仪器的结果仍然与方法特异性目标值相比较接近。可以计算可交换葡萄糖POC仪器与参考目标值之间的系统偏差,同时,这些额外的信息可以提供给这些参与者和制造商。

原始出处:

Tone Bukve, Sverre Sandberg, Commutability of a Whole-Blood External Quality Assessment Material for Point-of-Care C-Reactive Protein, Glucose, and Hemoglobin Testing

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2032009, encodeId=aaee2032009c9, content=<a href='/topic/show?id=64f249222b2' target=_blank style='color:#2F92EE;'>#床旁检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49222, encryptionId=64f249222b2, topicName=床旁检测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Apr 24 02:56:00 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069570, encodeId=608c20695e0b0, content=<a href='/topic/show?id=db43384135e' target=_blank style='color:#2F92EE;'>#可交换性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38413, encryptionId=db43384135e, topicName=可交换性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Mar 13 00:56:00 CST 2020, time=2020-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297840, encodeId=9f23129e84046, content=<a href='/topic/show?id=4eca5598c7' target=_blank style='color:#2F92EE;'>#C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5598, encryptionId=4eca5598c7, topicName=C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Mon Aug 05 05:56:00 CST 2019, time=2019-08-05, status=1, ipAttribution=)]
    2020-04-24 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=2032009, encodeId=aaee2032009c9, content=<a href='/topic/show?id=64f249222b2' target=_blank style='color:#2F92EE;'>#床旁检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49222, encryptionId=64f249222b2, topicName=床旁检测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Apr 24 02:56:00 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069570, encodeId=608c20695e0b0, content=<a href='/topic/show?id=db43384135e' target=_blank style='color:#2F92EE;'>#可交换性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38413, encryptionId=db43384135e, topicName=可交换性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Mar 13 00:56:00 CST 2020, time=2020-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297840, encodeId=9f23129e84046, content=<a href='/topic/show?id=4eca5598c7' target=_blank style='color:#2F92EE;'>#C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5598, encryptionId=4eca5598c7, topicName=C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Mon Aug 05 05:56:00 CST 2019, time=2019-08-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2032009, encodeId=aaee2032009c9, content=<a href='/topic/show?id=64f249222b2' target=_blank style='color:#2F92EE;'>#床旁检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49222, encryptionId=64f249222b2, topicName=床旁检测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Apr 24 02:56:00 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069570, encodeId=608c20695e0b0, content=<a href='/topic/show?id=db43384135e' target=_blank style='color:#2F92EE;'>#可交换性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38413, encryptionId=db43384135e, topicName=可交换性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Mar 13 00:56:00 CST 2020, time=2020-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297840, encodeId=9f23129e84046, content=<a href='/topic/show?id=4eca5598c7' target=_blank style='color:#2F92EE;'>#C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5598, encryptionId=4eca5598c7, topicName=C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Mon Aug 05 05:56:00 CST 2019, time=2019-08-05, status=1, ipAttribution=)]

相关资讯

Lancet:献血对身体到底有没有害,间隔多久献一次更安全?

对于捐献全血频率的限制主要是为了保障捐献者的健康。然而,在允许捐献的最高频率中,血液服务发生很大的变化。现研究人员将英国的标准做法与其他国家的较短的捐献间隔进行比较。

Plos One:复律后全血基因表达区分房颤和窦性心律

这项研究表明,SLC25A20,PDK4和NT-proBNP作为生物标志物可区分房颤与窦性心律的增量效用。AF期间SLC25A20和PDK4的表达升高表明AF中能量代谢的重要作用。